Trial Profile
Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2022
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Aspirin; Cilostazol; Clopidogrel
- Indications Coronary artery disease; Coronary stent thrombosis
- Focus Pharmacodynamics
- Acronyms OPTIMA-2; OPTIMAL
- 15 Aug 2020 Status changed from recruiting to completed.
- 16 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 16 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.